TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11771827

Group type: EXPERIMENTAL
Intervention: Insulin, glucose, and potassium (GIK) infusion using an euglycemic clamp technique.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no GIK infusion).
Number of subjects: 30
Study: 9316182

Group type: EXPERIMENTAL
Intervention: ACTH 4‐10 (1.25 mg intravenously, 30 minutes before testing)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8487647

Group type: EXPERIMENTAL
Intervention: Recombinant human TNF (50 micrograms/m2)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 6
Study: 2961815

Group type: EXPERIMENTAL
Intervention: HBIg (0.06 ml/kg) administered intramuscularly within 3 days after exposure, followed by a second dose 1 month later.
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: HBIg (0.06 ml/kg) administered within 3 days followed by HB vaccine (HEVAC‐B Pasteur 10 micrograms) within 7 days after exposure.
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (no immuno-prophylaxis)
Number of subjects: 137
Study: 2681882

Group type: EXPERIMENTAL
Intervention: L 841 A (vincristine + prednisone for remission induction, 18 Gy cranial irradiation + intrathecal methotrexate for CNS leukemia prophylaxis, maintenance with MTX iv alternating 5-day course of VCR + PDN + 6-mercaptopurine)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: L 841 B (asparaginase added)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: I 841 B (asparaginase added)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: I 841 C (asparaginase, Adriamycin, high-dose MTX 100 mg/kg)
Number of subjects: 144
Study: 30912707

Group type: EXPERIMENTAL
Intervention: Television Commercials (TVCs)
Number of subjects: 1855

Group type: EXPERIMENTAL
Intervention: Mobile messages for new mothers
Number of subjects: 1855

Group type: EXPERIMENTAL
Intervention: Mobile messages for mothers of 4-7 year-olds
Number of subjects: 1855

Group type: COMPARATOR
Intervention: Control TVC unrelated to handwashing
Number of subjects: 1855
Study: 28196278

Group type: EXPERIMENTAL
Intervention: Carbon fibre frameworks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Metal frameworks (control group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Comparison of bone resorption
Number of subjects: 42
Study: 26600636

Group type: EXPERIMENTAL
Intervention: Topical nepafenac 0.1%
Number of subjects: 70

Group type: COMPARATOR
Intervention: Topical flurbiprofen 0.03%
Number of subjects: 70
Study: 24229823

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg once daily
Number of subjects: 202

Group type: COMPARATOR
Intervention: Montelukast 4 to 5 mg once daily
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Montelukast
Number of subjects: 202
Study: 21841719

Group type: EXPERIMENTAL
Intervention: Heel elevation device plus pressure‐redistributing support surface
Number of subjects: 239

Group type: COMPARATOR
Intervention: Standard care (pressure‐redistributing support surface alone)
Number of subjects: 239
Study: 19826135

Group type: EXPERIMENTAL
Intervention: Elesclomol 213 mg/m² plus paclitaxel 80 mg/m² (E + P)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Paclitaxel 80 mg/m² alone
Number of subjects: 81
Study: 16731214

Group type: COMPARATOR
Intervention: Nortriptyline, fluoxetine, or placebo (double-blind methodology)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (nortriptyline or fluoxetine)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 92
Study: 15589019

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11506113

Group type: EXPERIMENTAL
Intervention: Train-of-four stimuli at 15-s intervals for 25 min (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single stimuli at 1.0 Hz for 10 min (Group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50-Hz tetanus of 5 seconds' duration before calibration (Group 3)
Number of subjects: 30
Study: 9525302

Group type: EXPERIMENTAL
Intervention: smoking intervention plus bronchodilator
Number of subjects: 5887

Group type: COMPARATOR
Intervention: smoking intervention plus placebo
Number of subjects: 5887

Group type: COMPARATOR
Intervention: no intervention
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: smoking intervention
Number of subjects: 5887
Study: 8355460

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (untreated hemodialysis patients)
Number of subjects: 35
Study: 3611686

Group type: EXPERIMENTAL
Intervention: Milk tolerance test (500 ml milk)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Lactose tolerance test
Number of subjects: 40
Study: 29150845

Group type: EXPERIMENTAL
Intervention: Sorbitol 3.2 g
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sorbitol 10.2 g
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sorbitol 13.4 g
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lamivudine 300 mg alone
Number of subjects: 16
Study: 26091986

Group type: EXPERIMENTAL
Intervention: Telephone call scenario
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Patient discomfort scenario
Number of subjects: 19

Group type: COMPARATOR
Intervention: Overall association
Number of subjects: 19
Study: 24269547

Group type: EXPERIMENTAL
Intervention: Supplemental oxygen
Number of subjects: 20

Group type: COMPARATOR
Intervention: No supplemental oxygen
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Capnography monitoring
Number of subjects: 20
Study: 22112014

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream (subgroup analysis)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vehicle cream (subgroup analysis)
Number of subjects: 40
Study: 20403940

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG) at a dose of 10^9 colony-forming units in 100 mL of a fermented milk product (LGG group, n = 376)
Number of subjects: 742

Group type: COMPARATOR
Intervention: Placebo (placebo group, n = 366)
Number of subjects: 742
Study: 17555526

Group type: EXPERIMENTAL
Intervention: Withdrawal of antiepileptic drugs (CBZ)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Nonwithdrawal group (control)
Number of subjects: 150
Study: 16640188

Group type: EXPERIMENTAL
Intervention: Intensive rehabilitation (TH-I) with earlier coordinative training due to unrestricted weight-bearing
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conservative rehabilitation (TH-C)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Both groups (TH-I and TH-C)
Number of subjects: 45
Study: 14624771

Group type: EXPERIMENTAL
Intervention: r‐hGH 0.05 mg/kg/day (high dose)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: r‐hGH 0.025 mg/kg/day (low dose)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 10418696

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLU)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control (TRP-free drink)
Number of subjects: 55
Study: 7719072

Group type: EXPERIMENTAL
Intervention: Monotherapy with prednisolone 1% eyedrops
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Monotherapy with indomethacin 1% eyedrops
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination therapy with prednisolone 1% + indomethacin 1% eyedrops
Number of subjects: 30
Study: 2043017

Group type: EXPERIMENTAL
Intervention: Pilocarpine hydrochloride (5-mg capsules, three times daily for 5 months)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pilocarpine hydrochloride
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo (randomly assigned for 1 month)
Number of subjects: 31
Study: 6167116

Group type: EXPERIMENTAL
Intervention: 5% benzoyl peroxide preparation
Number of subjects: 0
Study: 30861337

Group type: EXPERIMENTAL
Intervention: GSK3389404 (10 mg, 30 mg, 60 mg, 120 mg single doses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: GSK3389404 (30 mg, 60 mg, 120 mg multiple doses, once weekly for 4 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 29890048

Group type: EXPERIMENTAL
Intervention: ART initiated regardless of CD4 count (intervention arm)
Number of subjects: 900

Group type: COMPARATOR
Intervention: ART initiated according to national guidelines (control arm)
Number of subjects: 900
Study: 27821142

Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (no NPWT)
Number of subjects: 0
Study: 24198300

Group type: EXPERIMENTAL
Intervention: Intervention cohort (high ACR tertile)
Number of subjects: 400
Study: 22217118

Group type: EXPERIMENTAL
Intervention: Web-based intervention (password-protected website with information about colorectal cancer and screening options)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Printed format (control group)
Number of subjects: 391
Study: 19395585

Group type: EXPERIMENTAL
Intervention: Dasatinib 50 mg alone
Number of subjects: 24

Group type: COMPARATOR
Intervention: Famotidine 40 mg given 10 hours before dasatinib
Number of subjects: 24

Group type: COMPARATOR
Intervention: Antacid (Maalox) 2 hours before dasatinib
Number of subjects: 24

Group type: COMPARATOR
Intervention: Antacid (Maalox) coadministered with dasatinib
Number of subjects: 24
Study: 17224718

Group type: EXPERIMENTAL
Intervention: Modafinil (400 mg daily)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 15131729

Group type: EXPERIMENTAL
Intervention: Topical application using a body wash containing 0.15% vitamin E and 0.10% vitamin E acetate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Dietary supplementation with 400 IU alpha-tocopherol
Number of subjects: 0
Study: 11669085

Group type: EXPERIMENTAL
Intervention: Mistletoe preparation (Abnobaviscum Quercus) injected subcutaneously three times a week for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Pre-treatment observation for 6 months
Number of subjects: 25
Study: 9536925

Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg once daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Atrial natriuretic peptide infusion (0.01 microgram min-1 kg-1)
Number of subjects: 10
Study: 7665687

Group type: EXPERIMENTAL
Intervention: HHV‐6 detected in cervixes
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HHV‐7 detected in cervixes
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HHV‐6 and HHV‐7 co-detection
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: HHV‐6 variant type
Number of subjects: 72
Study: 2469243

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 795433

Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate cream and ointment (0.1%)
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate fatty ointment (0.1%)
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Diflucortolone valerate (all forms)
Number of subjects: 925

Group type: COMPARATOR
Intervention: Fluocortolone (Ultralan)
Number of subjects: 925
Study: 30745078

Group type: EXPERIMENTAL
Intervention: lidocaine 2% with epinephrine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% with epinephrine
Number of subjects: 112

Group type: COMPARATOR
Intervention: lidocaine 2%
Number of subjects: 112

Group type: COMPARATOR
Intervention: bupivacaine 0.5%
Number of subjects: 112
Study: 28685560

Group type: EXPERIMENTAL
Intervention: Doctor Tecar TherapyTM
Number of subjects: 60

Group type: COMPARATOR
Intervention: Laser therapy
Number of subjects: 60
Study: 25975558

Group type: EXPERIMENTAL
Intervention: Zhenggan Tang decoction
Number of subjects: 66

Group type: COMPARATOR
Intervention: Inosine tablets and vitamin C (Control)
Number of subjects: 66
Study: 23815742

Group type: EXPERIMENTAL
Intervention: Benidipine (2 mg daily, increased to 8 mg daily)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg daily, increased to 10 mg daily)
Number of subjects: 104
Study: 21528596

Group type: EXPERIMENTAL
Intervention: Calcichew D3 tablets and acupoint catgut embedding
Number of subjects: 105

Group type: COMPARATOR
Intervention: Calcichew D3 tablets (oral administration)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Calcichew D3 tablets and Xianling Gubao capsule (oral administration)
Number of subjects: 105
Study: 19210013

Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 214
Study: 16845799

Group type: EXPERIMENTAL
Intervention: Continuously slow intravenous arsenic trioxide (As2O3) infusion regimen for 24 hours at an infusion rate of 8 drips per minute, total infusion duration of about 18-21 hours daily, daily dosage of 0.16 mg/kg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine regimen with arsenic trioxide (As2O3) infusion at an infusion rate of 45-55 drips per minute, total infusion duration of about 2-3 hours daily, daily dosage of 0.16 mg/kg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Continuously slow intravenous arsenic trioxide (As2O3) infusion regimen
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine regimen with arsenic trioxide (As2O3) infusion
Number of subjects: 75
Study: 14665897

Group type: EXPERIMENTAL
Intervention: Concomitant use of sildenafil (100 mg) and a vacuum entrapment device (VED)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Sildenafil (100 mg)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Vacuum entrapment device (VED)
Number of subjects: 161
Study: 11707559

Group type: EXPERIMENTAL
Intervention: Dietitian-led intervention (Group A)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Dietitian-led intervention incorporating meal replacements (Group B)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Clinical office-based intervention incorporating meal replacements (Group C)
Number of subjects: 113
Study: 9815589

Group type: EXPERIMENTAL
Intervention: Alternating chemoradiotherapy (arm A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Partly accelerated radiotherapy alone (arm B)
Number of subjects: 40
Study: 9053968

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg intravenously)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control conditions (no intervention)
Number of subjects: 8
Study: 2083851

Group type: EXPERIMENTAL
Intervention: Terconazole, 240 mg, one dose per day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Terconazole, 80 mg, daily dose for three days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chlotrimazole, 200 mg, daily dose for three days
Number of subjects: 60
Study: 6161897

Group type: EXPERIMENTAL
Intervention: Macrodex 6% (500 ml Dextran 60 infusion)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 0.9% NaCl (500 ml)
Number of subjects: 10
Study: 30633331

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Relaxation Training (RT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Health Education Control (HE)
Number of subjects: 123
Study: 28353541

Group type: EXPERIMENTAL
Intervention: Home-based exercise program with improvements in exercise capacity (group 1)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Home-based exercise program with improvements in exercise capacity (group 2)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Home-based exercise program with reductions in exercise capacity (group 3)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Home-based exercise program with reductions in exercise capacity (group 4)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Home-based exercise program (all groups)
Number of subjects: 71
Study: 26011677

Group type: EXPERIMENTAL
Intervention: ZS-9 5 g
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: ZS-9 10 g
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: ZS-9 15 g
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study: 24403696

Group type: EXPERIMENTAL
Intervention: Combined manipulation and mobilization
Number of subjects: 20

Group type: COMPARATOR
Intervention: Mobilization only
Number of subjects: 20
Study: 21884310

Group type: EXPERIMENTAL
Intervention: Indirect priming using stories
Number of subjects: 106

Group type: COMPARATOR
Intervention: Explicit verbal instructions
Number of subjects: 106
Study: 20379631

Group type: EXPERIMENTAL
Intervention: InfinniumR paclitaxel‐eluting stent
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: SupralimusR sirolimus‐eluting stent
Number of subjects: 275

Group type: COMPARATOR
Intervention: Milennium MatrixR bare metal stent
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Sirolimus‐eluting stent
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Paclitaxel‐eluting stent
Number of subjects: 275
Study: 17353471

Group type: EXPERIMENTAL
Intervention: IV immunoglobulin (IVIG) 2 g/kg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (IV dextrose 5% in water)
Number of subjects: 51
Study: 15342212

Group type: EXPERIMENTAL
Intervention: Capillary INR monitoring
Number of subjects: 60
Study: 11152366

Group type: EXPERIMENTAL
Intervention: 100 mg/kg methionine
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 100 mg/kg methionine plus 2 g of vitamin C
Number of subjects: 8

Group type: COMPARATOR
Intervention: Matching placebos
Number of subjects: 8
Study: 8791244

Group type: EXPERIMENTAL
Intervention: Proximal sciatic nerve stimulation
Number of subjects: 36
Study: 1634718

Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion of bupivacaine and fentanyl
Number of subjects: 51

Group type: COMPARATOR
Intervention: Continuous intravenous infusion of fentanyl
Number of subjects: 51
Study: 6734455

Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 30168348

Group type: EXPERIMENTAL
Intervention: External focus instructions
Number of subjects: 63

Group type: COMPARATOR
Intervention: Internal focus instructions
Number of subjects: 63
Study: 30629280

Group type: EXPERIMENTAL
Intervention: Intranasal REMOXY ER (manipulated or intact)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ground oxycodone IR
Number of subjects: 36

Group type: COMPARATOR
Intervention: OxyContin ER
Number of subjects: 36
Study: 26864410

Group type: COMPARATOR
Intervention: Control (0 interventions)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Suggested alternatives (1 intervention)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Accountable justification (2 interventions)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: Peer comparison (3 interventions)
Number of subjects: 248
Study: 24211813

Group type: EXPERIMENTAL
Intervention: Levofloxacin (LVFX) 500 mg administered orally
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (normal pulmonary function)
Number of subjects: 10
Study: 22264436

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 20807407

Group type: EXPERIMENTAL
Intervention: Classification of hand eczema plus individual counselling
Number of subjects: 3181

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 3181
Study: 17237007

Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen with 5-fluorouracil and folinic acid (FUFOL)
Number of subjects: 5300

Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine
Number of subjects: 5300

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy
Number of subjects: 5300

Group type: COMPARATOR
Intervention: Chemoradiotherapy
Number of subjects: 5300
Study: 15978775

Group type: EXPERIMENTAL
Intervention: Onlay augmentation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sinus lift
Number of subjects: 100
Study: 11886484

Group type: EXPERIMENTAL
Intervention: E2 + T (trimegestone 0.5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: E2 (oestradiol 2 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: E2 + D (dydrogesterone 10 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 10460069

Group type: EXPERIMENTAL
Intervention: Clomipramine 25 mg/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Clomipramine 50 mg/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Clomipramine 75 mg/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Clomipramine 125 mg/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Clomipramine 200 mg/day
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Clomipramine (all doses)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Clomipramine and desmethylclomipramine serum levels
Number of subjects: 151
Study: 7798508

Group type: EXPERIMENTAL
Intervention: Bisoprolol (10 mg daily)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Nifedipine (2 x 20 mg)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Bisoprolol (20 mg daily)
Number of subjects: 330
Study: 2074163

Group type: EXPERIMENTAL
Intervention: naproxen sodium 550 mg bid
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: pizotyline 0.5 mg tid
Number of subjects: 176

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 176
Study: 7195146

Group type: EXPERIMENTAL
Intervention: Cow's milk diet
Number of subjects: 34

Group type: COMPARATOR
Intervention: Soya protein diet
Number of subjects: 34
Study: 30696533

Group type: EXPERIMENTAL
Intervention: Nasal spray containing silver vitellinate, hyaluronic acid and sodium benzoate
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline solution (sodium chloride 0.9%)
Number of subjects: 54
Study: 28058800

Group type: EXPERIMENTAL
Intervention: Negligible carbohydrate snacks (up to 5.1 g carbohydrate and 276.3 kJ per portion)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Absolute fasting
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Negligible carbohydrate snacks
Number of subjects: 20